Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport, Inc. (Nasdaq: CYRX) reported a fire incident on January 25, 2022, at its MVE Biological Solutions manufacturing facility in New Prague, Minnesota. The fire caused limited damage and no injuries were reported. Operations at the facility will be temporarily reduced until repairs are completed, which could affect financial results for Q1 and possibly Q2 of 2022. However, Cryoport expects insurance to cover a significant portion of the financial impact. The company continues to assess operations and will provide updates as necessary.
Cryoport (Nasdaq: CYRX) has announced a strategic partnership with Cell Matters to offer end-to-end cryopreservation services for therapies derived from leukapheresis, targeting both autologous and allogeneic cell therapies. This collaboration aims to enhance the supply chain for the life sciences industry and address the challenges faced by cell therapy manufacturers. Cryoport plans to expand its presence in the European market while continuously innovating its temperature-controlled solutions and consulting services to meet growing demand in regenerative therapies.
Cryoport, a leader in temperature-controlled supply chain solutions for life sciences, announced that CEO Jerrell Shelton and CFO Robert Stefanovich will present at the J.P. Morgan 40th Annual Healthcare Conference from January 10-13, 2022. Shelton's presentation is scheduled for January 12 at 9:00 a.m. ET. They will also engage in 1x1 virtual meetings during the conference. The presentation can be accessed via a webcast on the company’s website, with a replay available for 30 days.
Cryoport, Inc. (NASDAQ: CYRX) announced a registered direct placement of 3,072,038 shares at $81.10 per share. The placement, estimated to generate $248.6 million in net proceeds, will conclude on November 12, 2021. Funds will be used to repurchase $100.7 million of its 3.00% Convertible Senior Notes, totaling approximately $351.1 million including interest. The placement is contingent upon the completion of a separate offering of $350 million of convertible senior notes due 2026. Completion risks and potential market impacts on trading prices are noted.
Cryoport, Inc. (Nasdaq: CYRX) has announced the pricing of a private offering of $350 million in 0.75% convertible senior notes due 2026. The offering was increased from an initial $300 million. The notes, maturing on December 1, 2026, will accrue interest semi-annually and feature a conversion price of approximately $117.59 per share, offering a 45% premium over the last stock price of $81.10. Net proceeds are estimated at $339 million, aimed at repurchasing existing convertible notes and supporting general corporate purposes. The offering is set to close on November 12, 2021.
Cryoport, Inc. (Nasdaq: CYRX) announced its intention to offer $300 million of convertible senior notes due 2026 in a private offering. The company may grant initial purchasers an option for an additional $45 million of notes. The notes are senior and unsecured, maturing on December 1, 2026, and will pay interest semi-annually. Proceeds will be used to repurchase existing convertible notes and for general corporate purposes. The completion of the note offering is not contingent on a separate common stock placement, although the stock placement completion is dependent on the notes offering.
Cryoport, a leader in temperature-controlled supply chain solutions, plans to offer shares of its common stock through a registered direct placement. The number of shares and pricing will be determined based on market conditions. The company aims to use the net proceeds to repurchase a portion of its 3.00% Convertible Senior Notes due 2025 and for general corporate purposes. In a separate announcement, Cryoport intends to offer $300 million in aggregate principal of convertible senior notes due 2026. The completion of both placements is subject to market conditions.
Cryoport, Inc. (NASDAQ: CYRX) announced its Q3 2021 financial results, showcasing record revenues of $56.7 million, a 407% increase year-over-year, driven by a 371% rise in Biopharma/Pharma revenue to $46.0 million. This growth is attributed to strong demand across all business units, supporting 582 clinical trials, and commercial revenue from regenerative therapies. Despite the revenue boom, gross margins decreased due to acquisitions and rising operational costs. The company has significant cash reserves of $349.5 million and remains optimistic about future growth opportunities.
Summary not available.
Cryoport (NASDAQ: CYRX), a leader in temperature-controlled supply chain solutions, will report its third quarter 2021 financial results on November 4, 2021, after market close. Accompanying the results, a document titled 'Cryoport Third Quarter 2021 in Review' will be released at 4:05 PM ET. A conference call to discuss the results is scheduled for 5:00 PM ET on the same day. This call will include a Q&A session to address investor queries. The company supports critical cell and gene therapies and has been involved in numerous clinical trials globally.